EDIT · Editas Medicine, Inc.
$3.10
+0.16 (+5.44%)
At close · Aug 21
Market Cap
$451.53M
Shares
153.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.94
Open$3.17
Day$2.92–3.23
52W close$1.67–4.15
Avg vol 30d2.0M
Short int23.5M · 15.3% float · 18.2d
Short vol48%
Last earningsMay 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+14%
above
Price vs 50-day avg
+2%
above
RSI (14)
52
neutral
MACD trend
Positive
52-week position
51%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
+34%
trailing
YTD return
+43%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.28% of float · ▲ +5.7% MoM · 18.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
216 holders — mid 3-yr range
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+133%
Y/Y
EPS growth
+38%
Y/Y
Free cash flow
$-165.8M
Balance sheet
$88.0M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+14%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
51%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.28% of float · ▲ +5.7% MoM · 18.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
216 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 51%
Range high $4
vs 200-day avg +14%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EDIT
this stock
Editas Medicine, Inc.
|
$451.53M | +43.4% | +132.6% | — | 15.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.4% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EDIT | +4.6% | +7.7% | +33.6% | +14.0% | +43.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +6.6% | +4.4% | +22.5% | +11.9% | +31.6% |
Key facts
CIK
1650664
CUSIP
28106W103
13F (30d)
215 filings
191 filers
Visit website
Investor relations